X4 Pharmaceuticals

124 articles with X4 Pharmaceuticals

• 

  Founded by Genzyme Alumni, Cambridge's X4 Pharma Scores $27M

  11/16/2017

  The company plans to use the cash to advance its two lead drug programs into the clinic.

• X4 Pharmaceuticals Presents Clinical Data Demonstrating Immune Activation Through CXCR4 Pathway With X4P-001-IO

  11/10/2017

  The data, primarily generated from biopsies of tumors from melanoma patients, demonstrated important changes in the tumor microenvironment.

• X4 Pharma Release: First Clinical Data From Combination of X4P-001-IO and Keytruda (pembrolizumab) in Patients With Melanoma Will Be Presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

  11/3/2017

  X4P-001, an Orally Bioavailable CXCR4 Antagonist, Increases T-cell Infiltration in Human Metastatic Melanoma

• X4 Pharma Release: Clinical Data for X4P-001-IO in Combination With Inlyta (Axitinib) Demonstrated Encouraging Overall Response Rates (Including a Complete Response) and Disease Control Rates in Patients with Clear Cell Renal Cell Carcinoma

  10/30/2017

  The data were presented at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 29 in Philadelphia.

• Updated Clinical Data From Combination of X4P-001-IO and Inlyta (Axitinib) in Patients With Clear Cell Renal Cell Carcinoma Will Be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  10/26/2017

  X4 Pharmaceuticals today announced that the American Association for Cancer Research (AACR) has published Phase 1 data from an ongoing Phase 1/2 study of X4P-001-IO in combination with Inlyta® (axitinib), Pfizer’s VEGFR kinase inhibitor.

• X4 Pharma Release: Initial Clinical Trial Data For Combination Of X4P-001-IO And Inlyta (Axitinib) Demonstrate Encouraging Disease Control Rates And Durable Clinical Responses In Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

  9/11/2017

• X4 Pharma Release: First Data From Combination Of X4P-001-IO And Inlyta (Axitinib) In Patients With Clear Cell Renal Cell Carcinoma Will Be Presented At The European Society Of Medical Oncology 2017 Congress

  8/31/2017

• X4 Pharma Announces Rare Disease Research Collaboration With Yale

  8/2/2017

• X4 Pharma Announces Initiation Of The Phase II Expansion Of Its Phase I/II Study Of X4P-001 In Patients With Advanced Clear Cell Renal Cell Carcinoma

  5/25/2017

• X4 Pharma Announces Initiation Of A Phase 2/3 Clinical Study Of X4P-001-LD In Patients With WHIM Syndrome, A Rare Genetic Primary Immunodeficiency Disease

  1/30/2017

• X4 Pharma Release: Company Announces Initiation Of Clinical Study Of X4P-001 In Combination With Opdivo For Patients With Advanced Clear Cell Renal Cell Carcinoma

  1/26/2017

• X4 Pharma Release: Company Appoints Dr. Sudha Parasuraman As Chief Medical Officer

  1/23/2017

• X4 Pharma Announces New Data For Lead Candidate X4P-001 In Renal Cell Carcinoma At EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium

  11/30/2016

• X4 Pharma Appoints Nancy Lurker As Chair Of Board Of Directors

  10/5/2016

• X4 Pharma Announces Initiation Of Phase Ib Study Of X4P-001 In Patients With Resectable Stage III And Stage IV Melanoma

  9/27/2016

• X4 Pharma To Present At The 23rd Annual Biocentury Newsmakers In The Biotech Industry Conference

  9/7/2016

• X4 Pharma To Present At Canaccord Genuity’s 36th Annual Growth Conference

  8/8/2016

• X4 Pharma Appoints John K. Celebi As Chief Operating Officer

  6/13/2016

• X4 Pharma Announces Initiation Of Phase 1/2 Study Of X4P-001 In Patients With Advanced Clear Cell Renal Cell Carcinoma

  5/9/2016

• X4 Pharma Announces Data Presentation For Lead Candidate X4P-001 At AACR Annual Meeting

  4/20/2016